Publications

2009

Nagel R, Clijsters L, Agami R. ReThe miRNA-192/194 cluster regulates the Period gene family and the circadian clock.
FEBS J. 2009 Aug 13.

Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T, Holland EC. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.
Genes Dev. 2009 Jun 1;23(11):1327-37.

Scheel AH, Beyer U, Agami R, Dobbelstein M. Immunofluorescence-based screening identifies germ cell associated microRNA 302 as an antagonist to p63 expression.
Cell Cycle. 2009 May 1;8(9):1426-32. Epub 2009 May 27.

Bartolomé RA, Ferreiro S, Miquilena-Colina ME, Martínez-Prats L, Soto-Montenegro ML, García-Bernal D, Vaquero JJ, Agami R, Delgado R, Desco M, Sánchez-Mateos P, Teixidó J. The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs.
Am J Pathol. 2009 Feb;174(2):602-12. Epub 2009 Jan 15.

Elkon R, Agami R. Removal of AU bias from microarray mRNA expression data enhances computational identification of active microRNAs.
PLoS Comput Biol. 2008 Oct 3;4(10):e1000189.

2008

Zlotorynski E, Agami R. A PASport to cellular proliferation.
Cell. 2008 Jul 25;134(2):208-10. Preview.

Kedde M, Agami R. Interplay between microRNAs and RNA-binding proteins determines developmental processes.
Cell Cycle. 2008 Apr;7(7):899-903. Epub 2008 Jan 24. Review.

Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. miR-148 targets human DNMT3b protein coding region.
RNA. 2008 May;14(5):872-7. Epub 2008 Mar 26.

Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Puré E, Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis.
Nat Cell Biol. 2008 Feb;10(2):202-10. Epub 2008 Jan 13.

2007

Kedde M, Strasser MJ, Boldajipour B, Vrielink JA, Slanchev K, le Sage C, Nagel R, Voorhoeve PM, van Duijse J, Ørom UA, Lund AH, Perrakis A, Raz E, Agami R. RNA-binding protein Dnd1 inhibits microRNA access to target mRNA.
Cell. 2007 Dec 28;131(7):1273-86.

le sage C, Nagel R, Agami R. Diverse Ways to Control p27(Kip1) Function: miRNAs Come into Play.
Cell Cycle. 2007 Aug 16;6(22) [Epub ahead of print]

le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, Farace MG, Agami R. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation.
EMBO J. 2007 Aug 8;26(15):3699-708. Epub 2007 Jul 12.

Agami R. All roads lead to IKKepsilon.
Cell. 2007 Jun 15;129(6):1043-5.

agiv Y, Bai L, Wei DG, Agami R, Savage PB, Teyton L, Bendelac A. A distal effect of microsomal triglyceride transfer protein deficiency on the lysosomal recycling of CD1d.
J Exp Med. 2007 Apr 16;204(4):921-8. Epub 2007 Apr 2.

Voorhoeve PM and Agami R. Classifying microRNAs in cancer: The good, the bad and the ugly
BBA - Reviews on Cancer. Jun;1775(2):274-82.

2006

Kedde M, le Sage C, Duursma A, Zlotorynski E, van Leeuwen B, Nijkamp W, Beijersbergen R, and Agami R. Telomerase-independent Regulation of ATR by Human Telomerase RNA
J. Biol. Chem., Vol. 281, Issue 52, 40503-40514, December 29, 2006

le Sage C. and Agami R. Immense promeses for tiny molecules: Uncovering miRNA functions.
Cell Cycle. 2006 Jul 1;5(13):1415-1421.

Voorhoeve PM, le Sage C, Schrier M, Gillis AJM, Stoop H, Nagel R, Liu YP, van Duijse Y, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G,Nojima H, Looijenga, LHJ and Agami R. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.
Cell. 2006 Mar 24;124(6):1169-81.

2005

Duursma A, Agami R. CDK-dependent stabilization of Cdc6: linking growth and stress signals to activation of DNA replication.
Cell Cycle. 2005 Dec;4(12):1725-8. Epub 2005 Dec 22.

Schwartz M, Zlotorynski E, Goldberg M, Ozeri E, Rahat A, le Sage C, Chen BP, Chen DJ, Agami R, Kerem B. Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability.
Genes Dev. 2005 Nov 15;19(22):2715-26.

Duursma A, Agami R. p53-dependent regulation of Cdc6 protein stability controls cellular proliferation.
Mol Cell Biol. 2005 Aug;25(16):6937-47.

Kolfschoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM, Agami R. A Genetic Screen Identifies PITX1 as a Suppressor of RAS Activity and Tumorigenicity.
Cell. 2005 Jun 17;121(6):849-58.

Einav Y, Agami R, Canaani D. shRNA-mediated RNA interference as a tool for genetic synthetic lethality screening in mouse embryo fibroblasts.
FEBS Lett. Jan 3;579(1):199-202.

2004

Gagrica, S., Hauser, S., Kolfschoten, I., Osterloh, L., Agami, R., and Gaubatz, S. Inhibition of oncogenic transformation by mammalian Lin-9, a pRB-associated protein.
EMBO J 23, 4627-4638.

Zhong, X., Shen, Y., Ballar, P., Apostolou, A., Agami, R., and Fang, S. . AAA ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation.
J Biol Chem 279, 45676-45684.

Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R. A large-scale RNAi screen in human cells identifies new components of the p53 pathway.
Nature 428, 431-437.

Voorhoeve, P. M., and Agami, R. Unraveling human tumor suppressor pathways: a tale of the INK4A locus.
Cell Cycle 3, 616-620.

2003

Voorhoeve, P. M., and Agami, R. The tumor suppressive functions of the human INK4A locus.
Cancer Cell, 4, 311-319.

Kolfschoten I., and Agami, R. Allelic gene inactivation: pinpointing the problem.
Gene Therapy, 10, 1931-1932.

Duursma A. M. and Agami, R. Ras interference as cancer therapy.
Seminars in Cancer Biology, 13, 267-273.

van de Wetering, M., Oving, I., Muncan, V., Pon Fong, M. T., Brantjes, H., van Leenen, D., Holstege, F. C., Brummelkamp, T. R., Agami, R., and Clevers, H. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector.
EMBO Rep., 4, 609-615.

Lens, S. M., Wolthuis, R. M., Klompmaker, R., Kauw, J., Agami, R., Brummelkamp, T., Kops, G., and Medema, R. H. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension.
EMBO J., 22, 2934-2947.

Voorhoeve, P. M., and Agami, R. Knockdown stands up.
Trends Biotechnol, 21, 2-4.

2002

Agami, R. RNAi and related mechanisms and their potential use for therapy.
Curr Opin Chem Biol. 2002 Dec;6(6):829-34.

Brummelkamp, T. R., Bernards, R. and Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference.
Cancer Cell, 2, 243-247.

Brummelkamp, T. R., Bernards, R. and Agami, R. A system for stable expression of short interfering RNAs in mammalian cells.
Science, 295.

Agami, R. and Bernards, R. Convergence of mitogenic and DNA damage signaling in the G1 phase of the cell cycle.
Cancer letters, 177, 111-118.

Agami, R. and Bernards, R. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage.
Cell, 102, 55-66.